Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunitybio Inc (NQ: IBRX )

5.291 +0.281 (+5.61%)
Streaming Delayed Price Updated: 2:10 PM EST, Nov 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunitybio Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Tuesday morning! 
Via InvestorPlace
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio: Q4 Earnings Insights
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023
IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END 
Via FinancialNewsMedia
5 Stocks with Unusually Large Short Interest
With the market soaring to new heights, fueled by the tech sector and hype surrounding AI, high short-interest stocks are again under the spotlight. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
From ImmunityBio
Via Business Wire
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
From ImmunityBio
Via Business Wire
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of Intuitive Machines, Inc. (NASDAQ: LUNR) fell sharply in today’s pre-market trading. Intuitive Machines revealed Friday that its lunar lander, Odysseus, encountered a mishap during a touchdown... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the trading week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning! 
Via InvestorPlace
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results. 
Via Benzinga
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
From ImmunityBio
Via Business Wire
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
From ImmunityBio, Inc.
Via Business Wire
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024
Lower interest rates and the low valuation of many biotech stocks are likely to result in many drug maker stocks being acquired in 2024. 
Via InvestorPlace
Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates. 
Via Benzinga
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
From ImmunityBio, Inc.
Via Business Wire
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
Why Rocket Lab Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of Rocket Lab USA, Inc. (NASDAQ: RKLB) shares rose sharply in pre-market trading after the company announced a new $515 million contract with a U.S. government customer. 
Via Benzinga
Toro Posts Upbeat Results, Joins Clear Channel Outdoor, Marathon Digital And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones index falling around 50 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Jim Cramer Likes This Industrial Stock 'Even Up Here,' As For ImmunityBio? 'It's Risky'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Trane Technologies plc (NYSE: TT) so much. 
Via Benzinga
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.